Hemab Therapeutics Holdings closed at $45.09 on Nov 4, up 4.62% — matching its highest close since Sep 11. Volume of 499.9K shares was 1.13× its 20-day average (close to normal).
Split-adjusted performance: +58.9% over one month.
Short interest was 3.2M shares at the Oct 15 settlement, down 6.8% from the prior report (20.4% of float, 7.8 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| COAGHemab Therapeutics Holdings | $45.09 | +4.62% | — | — | — | — | $2.11B | |
| BCRXBioCryst Pharmaceuticals | $8.24 | −3.85% | −6.7% | +33.6% | 35.9% | — | $2.11B | Compare |
| VIRVir Biotechnology | $11.77 | +4.90% | +14.4% | +19582.5% | 33.5% | — | $1.99B | Compare |
| REPLReplimune Group | $20.69 | +0.19% | +501.5% | — | — | — | $1.96B | Compare |
| RXRXRecursion Pharmaceuticals | $3.88 | +5.43% | +13.1% | +258.5% | −641.6% | — | $2.32B | Compare |
| VCELVericel | $45.48 | +10.68% | +23.7% | +22.5% | 2.8% | 96.2 | $2.33B | Compare |
| ADMAADMA Biologics | $10.48 | −5.67% | +4.0% | +2.0% | 30.4% | 13.9 | $2.35B | Compare |
| MAZEMaze Therapeutics | $33.38 | +3.50% | +26.1% | — | — | — | $1.85B | Compare |
| NVAXNovavax | $10.65 | +10.02% | +13.8% | −76.3% | −94.2% | — | $1.76B | Compare |
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
